A double-blind, multicentre, parallel group, randomised, controlled trial to evaluate the possible benefit of isoniazid dose adjustment according to the genotype for NAT2 (arylamine N-acetyltransferase type 2) in patients with pulmonary tuberculosis

Registry ID

EUCTR2007-000224-41

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE3

Sponsor

University of Cologne

Start date

2007-03-12

Completion date

2010-09-15

Last update

2026-08-16

Conditions

• pulmonary tuberculosis

Summary

The study is conducted to compare safety and efficacy of isoniazid administered as an adjusted dose based on NAT2 genotype and as a standard dose

Locations

• , , Germany
• , , Bulgarian Drug Agency

View on source registry